Skip to main content
Fig. 3 | European Journal of Medical Research

Fig. 3

From: A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

Fig. 3

Multiplex cytokine analysis in all available samples from patients with PFS of≥ 4 months vs. < 4 months. At baseline, patients with PFS ≥ 4 months had significantly lower levels of epidermal growth factor (EGF; p = 0.0372; Welch’s T test; A). Patients with PFS ≥ 4 months had significantly lower levels of interleukin-27 (IL-27) at week 7 (p = 0.0403, Welch’s T test; B)

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us